AST Asterias Biotherapeutics, Inc.

-0.20  -6%
Previous Close 3.40
Open 3.35
Price To book 3.75
Market Cap 157.64M
Shares 49,263,000
Volume 56,321
Short Ratio 10.81
Av. Daily Volume 181,703

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 2017.
Non-small cell lung cancer (NSCLC)
Phase 1/2 six and nine-month data released January 24, 2017. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017. Data Monitoring Committee (DMC) noted April 25 to continue trial as planned.
Cervical spinal cord injury
Phase 2b planned for 2018.
Acute myeloid leukemia (AML)

Latest News

  1. Asterias Biotherapeutics Announces Top Leadership Transition
  2. Asterias Biotherapeutics posts 1Q loss
  3. Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
  4. New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
  5. Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017
  6. Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
  7. Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
  8. Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Cervical Spinal Cord Injury
  9. Implied Volatility Surging for Asterias Biotherapeutics (AST) Stock Options
  10. ETFs with exposure to Asterias Biotherapeutics, Inc. : April 17, 2017
  11. Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
  12. Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
  13. Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
  14. Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
  15. BioTime Reports $56M Non-Cash Gain On Deconsolidation
  16. Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
  17. Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
  18. Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study